<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43520">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01859325</url>
  </required_header>
  <id_info>
    <org_study_id>130141</org_study_id>
    <secondary_id>13-I-0141</secondary_id>
    <nct_id>NCT01859325</nct_id>
  </id_info>
  <brief_title>Therapeutic Vaccine for HIV</brief_title>
  <official_title>A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profectus Biosciences, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - In most people who have human immunodeficiency virus (HIV), the immune system cannot
      control or cure the infection. Antiretroviral therapy drugs can keep the amount of HIV virus
      low for a long time. However, this treatment does not remove the virus from the body. In the
      vast majority of patients antiretroviral therapy also will not protect the body from the
      virus once treatment stops. Researchers want to see if therapeutic vaccination can help
      people with HIV. Therapeutic vaccination means giving vaccines to treat an infection that
      someone already has (HIV, in this case). It may help the body's immune system attack the
      infection. This study will look at different measures of HIV infection after receiving
      either therapeutic vaccination or a placebo.

      Objectives:

      - To see whether therapeutic vaccination is safe and can affect how the body responds to HIV
      infection.

      Eligibility:

      - Individuals between 18 and 65 years of age who have HIV and are taking antiretroviral
      therapy drugs.

      Design:

        -  Participants will be screened with a physical exam and medical history. Blood and urine
           samples will be collected.

        -  During the screening visit and throughout the study until week 56, participants will
           continue to take their HIV medications.

        -  Participants will be divided into two groups. One group will have the study vaccines.
           The other will have a placebo.

        -  The first study vaccine or placebo will be given in weeks 4, 12, and 36. The second
           study vaccine or the placebo will be given in weeks 24 and 48. Blood samples and other
           tests will be given at each visit.

        -  After the study visit at week 56, participants will stop their HIV medications until
           week 72. From weeks 58 through 72, they will come in every 2 weeks for study visits;
           each visit will take about 1 hour to complete. These visits will look at the body   s
           response to the vaccines and their HIV viral load. After week 72, participants will
           re-start their HIV medications.

        -  There will be follow-up study visits from weeks 76 to 96, with blood tests and other
           studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The advent of combination antiretroviral therapy (cART) has dramatically improved the
      clinical outcome in human immunodeficiency virus (HIV)-infected individuals through
      sustained reduction in viral replication. However, it has become clear that cART alone
      cannot eradicate HIV in infected individuals, likely in part due to the persistence of viral
      reservoirs in peripheral blood and various tissue compartments. Consequently, a major thrust
      of HIV research over the past several years has been to develop therapeutic strategies that
      can eliminate persistent viral reservoirs and boost host immunity to control viral
      replication upon discontinuation of cART. Therapeutic HIV vaccination is one approach that
      could potentially achieve these goals through vaccine-induced improvement in HIV-specific
      immune responses and/or by direct reactivation of HIV-specific CD4+ memory T cells that
      harbor latent HIV. An effective therapeutic vaccine could augment immunologic control of HIV
      infection and potentially obviate the need for chronic cART.

      The current study is an exploratory randomized, 2-arm (1:1), double-blind,
      placebo-controlled trial evaluating the safety and efficacy of an HIV-1 multiantigen plasmid
      DNA (HIV-MAG pDNA) vaccine prime in combination with an interleukin-12 plasmid DNA (IL-12
      pDNA) adjuvant delivered by in vivo electroporation followed by a recombinant vesicular
      stomatitis virus vector containing the HIV-1 gag gene (rVSV HIV gag) booster vaccine in
      subjects on cART who started therapy during acute or early HIV infection.

      Subjects will be randomized to receive placebo or the HIV-MAG pDNA (3000   g) vaccine prime
      and IL-12 pDNA adjuvant (1000   g) at week 0, 4, 12, and 36, and the rVSV HIV gag booster
      vaccine (1x107 plaque-forming units) at week 24 and 48. The HIV-MAG pDNA vaccine prime and
      IL-12 pDNA adjuvant will be administered as 2 IM injections, 1 into each deltoid, with
      electroporation using the Ichor TDS device, while the rVSV HIV gag booster vaccine will be
      administered as 2 conventional IM injections, 1 into each deltoid. After the week 56 visit,
      all subjects will undergo an analytical treatment interruption to determine if the
      vaccination strategy results in an improved immune control of viral replication, as
      evidenced by a blunted or absent rebound in HIV plasma viremia. All subjects will be
      followed through week 96 for safety and efficacy parameters.

      The study population includes HIV-infected adults who began cART during acute or early
      infection. Subjects must be receiving an effective cART regimen, with a CD4 cell count of &gt;
      450 cells/mm3 at screening, and they must have documented viral suppression below the limit
      of detection for greater than1 year. The rationale for testing the study vaccine regimen in
      this subject population is because these individuals may have a relatively preserved immune
      function, which could be augmented by therapeutic vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of the study vaccines in subjects who began cART during acute or early HIV-1 infection.</measure>
    <time_frame>Vaccine Phase</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory Objectives1. To assess the effect of the study vaccines on the rate of decay of the HIV-infected, CD4+ T-cell reservoir.2. To determine the immunogenicity of the study vaccines.</measure>
    <time_frame>Through out the whole study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of the study vaccines as determined by its effect on rebound viremia following ATI.</measure>
    <time_frame>Through out the whole study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV</condition>
  <condition>Therapeutic Vaccine</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-MAG pDNA vaccine prime will be administered at a dose of 3000   g (1500   g of the HIV-1 gag/pol plasmid and 1500   g of the HIV-1 net/tat/vif, env plasmid) at week 0, 4, 12, and 36. Each construct of HIV-MAG pDNA vaccine (1500   g each) will be mixed and combined with 1000   g of the IL-12 pDNA adjuvant. The resulting mixture will be divided into 2 IM injections and administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid with EP using the TDS device. IL-12 pDNA adjuvant will be mixed with the HIV-MAG pDNA vaccine prime, as noted above, and administered at a dose of 1000   g (500   g in each IM injection) at week 0, 4, 12, and 36. rVSV HIV gag booster vaccine--The total dose, 1x107 pfu, will be administered as 1 mL (5x106 pfu) IM injection in the left deltoid and 1 mL (5x106 pfu) IM injection in the right deltoid at week 24 and 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for the IL-12 pDNA adjuvant and HIV-MAG pDNA vaccine (sodium chloride for injection, USP 0.9%) will be administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid at weeks 0, 4, 12, and 36 with EP using the TDS device. Placebo for the rVSV HIV gag (sodium chloride for injection, USP 0.9%) will be administered as 1 mL IM injection in the left deltoid and 1 mL IM injection in the right deltoid at week 24 and 48.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVSV</intervention_name>
    <description>Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-12 pDNA adjuvant</intervention_name>
    <description>plasmid DNA containing human IL-12 gene</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-Mag pDNA</intervention_name>
    <description>plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Age, 18-65 years.

               2. Institution of cART within 12 weeks of being diagnosed with acute or early HIV-1
                  infection.

                  Acute HIV-1 infection is defined as:

                    1. Detectable plasma HIV-1 RNA levels of greater than 2000 copies/mL with a
                       negative result from an HIV-1 EIA, or

                    2. Positive result from an HIV-1 EIA with a negative or indeterminate result
                       from an HIV-1 western blot that subsequently evolves to a confirmed
                       positive result, or

                    3. Negative result from an HIV-1 EIA within the past 4 months and HIV-1 RNA
                       levels of greater than 400,000 copies/mL, in the setting of a potential
                       exposure to HIV-1.

                  Early HIV-1 Infection is defined as:

                    1. Negative result from an HIV-1 EIA within 6 months prior to a positive
                       result from an HIV-1 EIA and an HIV-1 western blot.

                    2. Negative result from a rapid HIV-1 test within 1 month prior to a positive
                       result from an HIV-1 EIA and an HIV-1 western blot.

                    3. Presence of low level of HIV antibodies as determined by having a positive
                       EIA or a positive Western blot with a non-reactive detuned EIA according to
                       a serologic testing algorithm for recent infection.

               3. CD4+ cell count greater than 450 cells/mm3 at screening.

               4. Documentation of continuous cART treatment with suppression of plasma viral
                  level below the limit of detection for greater than 1 year. Subjects with a
                  single    blip    (i.e., detectable viral levels on cART) prior to randomization
                  may be included provided they satisfy the following criteria:

                    1. The blips are  less than 400 copies/mL, and

                    2. Succeeding viral levels return to levels below the limit of detection on
                       subsequent testing.

               5. Willingness to undergo ATI.

               6. Laboratory values within pre-defined limits at screening:

                    -  Absolute neutrophil count greater than 1,000/mm3.

                    -  Hemoglobin levels greater than 10.0 g/dL for men and greater than 9.0 g/dL
                       for women.

                    -  Platelet count greater than 100,000/mm3.

                    -  Prothrombin time (PT) and partial thromboplastin time (PTT) less than 1.5
                       upper limit of normal (ULN).

                    -  Estimated or a measured creatinine clearance rate of greater than 60 mL/min
                       as determined by the NIH Clinical Center laboratory.

                    -  AST and ALT levels of less than 2.5 x ULN.

               7. Willingness to have samples stored for future research.

               8. Women of childbearing potential must have a negative pregnancy test result.

                    -  They must agree to use an adequate form of contraception:

                         -  Hormonal contraception.

                         -  Male or female condoms with or without a spermicidal

                         -  Diaphragm or cervical cap with a spermicidal.

                         -  Intrauterine device.

        EXCLUSION CRITERIA:

          1. Allergy to amide-type local anesthetics (bupivacaine (Marcaine), lidocaine
             (Xylocaine), Mepivacaine (Polocaine/Carbocaine), etidocaine (Duranest), prilocaine
             (Citanest, EMLA cream).

          2. Chronic hepatitis B, as evidenced by a positive test for hepatitis B surface antigen
             (HBsAg), or chronic hepatitis C virus (HCV) infection, as evidenced by a positive
             test for HCV RNA. Subjects with a positive test for HCV antibody and a negative test
             for HCV RNA are eligible.

          3. Changes in cART regimen due to virologic breakthrough.

          4. HIV immunotherapy or vaccine(s) received within 1 year prior to screening.

          5. Any licensed or experimental non-HIV vaccination (e.g., hepatitis B, influenza,
             pneumococcal polysaccharide) received within 4 weeks prior to study entry.

          6. Interruption of cART for greater than 3 months since its initiation. 8. Any active
             malignancy that may require systemic chemotherapy or radiation therapy.

          7. Pregnancy or planned pregnancy during the study period or breastfeeding.

          8. Any active malignancy that may require systemic chemotherapy or radiationtherapy.

          9. Immunosuppressive medications received within 6 months before the first study
             vaccination (Not excluded: (1) corticosteroid nasal spray for allergic rhinitis; (2)
             topical corticosteroids for mild, uncomplicated dermatitis; or (3) oral/parenteral
             corticosteroids administered for non-chronic conditions not expected to recur (length
             of therapy less than or equal to10 days, with completion in greater than or equal to
             30 days prior to enrollment).

         10. Evidence of hepatic decompensation in subjects with cirrhosis: history of ascites,
             hepatic encephalopathy, or bleeding esophageal varices, or screening laboratory
             results with any of the following:

               1. International normalized ratio of greater than or equal to1.5 x ULN.

               2. Serum albumin less than 3.2 g/dL.

               3. Serum total bilirubin greater than 1.8 x ULN, unless history of Gilbert's
                  disease or deemed related to treatment with atazanavir.

         11. History or other clinical evidence of:

               1. Significant or unstable cardiac disease (e.g., angina, congestive heart failure,
                  recent myocardial infarction, significant arrhythmia).

               2. Severe illness, malignancy, immunodeficiency other than HIV, or any other
                  conditions that, in the opinion of the investigator, would make the subject
                  unsuitable for the study.

               3. AIDS-defining condition.

         12. Known allergy or sensitivity to the components of the investigational therapy.

         13. History of significant cardiac arrhythmia (e.g., supraventricular tachycardia,
             ventricular tachycardia, and atrial fibrillation/flutter).

         14. Active drug or alcohol use or any dependence other pattern of behaivor that, in the
             opinion of the investigator, would interfere with adherence to study requirements.

         15. Any active systemic inflammatory or autoimmune disease or condition.

         16. Presence of implanted electronic medical device (e.g., pacemaker, implantable cardiac
             defibrillator) or surgical/traumatic metal implant in the upper limb and/or upper
             torso.

         17. Neurological or neuropsychiatric disorder that may interfere with the assessment of
             safety (e.g., frequent recurring headaches, for example, a pattern of greater than 1
             headache/month affecting activities of daily living/work, frequent or
             severe/complicated migraines, cluster headaches); or history of encephalitis,
             narcolepsy, stroke with sequelae, moderate/severe major depressive disorder,
             moderate/severe bipolar disorder, seizure disorder.

         18. Deltoid skinfold measurements (by caliper) of greater than 40 mm.

         19. Body mass index greater than 40.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C Sneller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen R Gittens</last_name>
    <phone>(301) 496-9320</phone>
    <email>gittenskr@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael C Sneller, M.D.</last_name>
    <phone>(301) 496-0491</phone>
    <email>msneller@niaid.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@mail.cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2013-I-0141.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 3;376(9734):49-62. doi: 10.1016/S0140-6736(10)60676-9. Review.</citation>
    <PMID>20609987</PMID>
  </reference>
  <reference>
    <citation>Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.</citation>
    <PMID>19265012</PMID>
  </reference>
  <reference>
    <citation>Trono D, Van Lint C, Rouzioux C, Verdin E, Barr√©-Sinoussi F, Chun TW, Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010 Jul 9;329(5988):174-80. doi: 10.1126/science.1191047. Review.</citation>
    <PMID>20616270</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-MAG pDNA Prime</keyword>
  <keyword>HIV Therapy</keyword>
  <keyword>Therapeutic Vaccine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
